Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 20/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21037498 | 0.83 | MAP3K12 (0.55) | MAP3K12 | |
| SCHEMBL16220038 | 0.82 | MAP3K12 (0.80) | MAP3K12 | |
| SCHEMBL20068770 | 0.80 | MAP3K12 (0.64) | MAP3K12 | |
| SCHEMBL21688453 | 0.80 | MAP3K12 (0.64) | MAP3K12 | |
| SCHEMBL16220367 | 0.79 | MAP3K12 (1.00) | MAP3K12 | |
| SCHEMBL16220486 | 0.79 | MAP3K12 (1.00) | MAP3K12 | |
| SCHEMBL19771659 | 0.78 | MAP3K12 (0.71) | MAP3K12 | |
| SCHEMBL16220233 | 0.78 | MAP3K12 (0.84) | MAP3K12 | |
| SCHEMBL16220084 | 0.77 | MAP3K12 (0.91) | MAP3K12 | |
| SCHEMBL16220371 | 0.77 | MAP3K12 (1.00) | MAP3K12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180110864-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180110864-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | PTGIR, PTGIS, CA2 | MAP3K12 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.